DUSP5 and pachyonychia congenita: Along this line, an IHC study showed that DUSP5 is downregulated in PC with respect to normal tissues and that lower DUSP5 expression is associated with cancer progression and poor prognosis, pointing to the ability of DUSP5 to act as an oncosuppressor in PC [111].